Greyledge Technologies

What Greyledge Technologies does

Greyledge Technologies, operating as Greyledge Biotech, is a privately held U.S. biotechnology company founded in 2010 and incorporated in Nevada, with operational presence in Edwards, Colorado. The company creates autologous biologic preparations intended to enable physicians to optimize the practice of regenerative medicine — that is, it provides lab-prepared, patient-derived biologic products (such as platelet-rich plasma or similar autologous concentrates) used by clinicians in orthopedic, sports medicine, and related regenerative treatment workflows. The company sells into the clinical/physician segment rather than directly to consumers, positioning itself as a specialized laboratory service partner for regenerative medicine practitioners.

The company operates with a very small team (1-10 employees) and a lean infrastructure, as evidenced by its minimal public-facing digital presence (the company website was under maintenance at the time of data collection) and limited publicly disclosed operational detail. No specific product catalog, pricing model, or distribution channel information is available in the public record. Founder and CEO David Karli leads the organization. Across its lifetime the company has raised approximately $7 million cumulatively through exempt securities offerings, with the largest single raise of $4.34 million occurring in 2022 under an SEC Form D filing, followed by a much smaller $183,325 round in March 2025.

The business model appears to be a specialized laboratory-services revenue model, monetizing autologous biologic preparation as a per-procedure or per-physician-account service, though pricing mechanics, customer count, and revenue figures have not been publicly disclosed. The company does not report marketing channels, partnership relationships, patents, or regulatory clearances in the available data, leaving significant gaps around competitive positioning and commercial scale.

Name

Greyledge Technologies

Legal name

Greyledge Technologies, Inc.

Website

https://greyledgebiotech.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

Greyledge Technologies (Greyledge Biotech) is a privately held U.S. biotechnology company founded in 2010 that develops autologous biologic preparations, enabling physicians to deliver regenerative medicine treatments. The company operates as a small specialty laboratory-services provider serving the clinical regenerative medicine market.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833), Services-Medical Laboratories (8071)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE)

Keywords

• Autologous biologic preparations
• Regenerative medicine products
• Point-of-care biologics
• Biologic therapy systems
• Cell-based therapeutics

Headquarters

HQ city

Edwards

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain

Core offering

Greyledge Technologies (DBA Greyledge Biotech) creates autologous biologic preparations that enable physicians to optimize the practice of regenerative medicine. The company supplies lab-produced autologous biologics intended for use by physician practices in regenerative medicine procedures.

Product overview

Greyledge Technologies (also referred to as Greyledge Biotech) is a Nevada-based biotechnology company. Based on available source data, specific product names, modules, or service offerings have not been identified. The company website was under maintenance at the time of data collection, with no product portfolio information available.

Differentiator

Problem solved

Functional benefit

Products and services

• Autologous Biologic Preparations

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves5 records

Expansion highlights2 records

Market position

Weaknesses4 records

Competitive moat3 records

Customer concentration

• Facebookfacebook.com/greyledgetechnologies
• LinkedInlinkedin.com/company/greyledgebiotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Greyledge Technologies